Want to see HK:2158 full AI Analyst Report?
Top Page
Yidu Tech, Inc.
(2158)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$5.50
▼(-1.43% Downside)
Action:Upgraded
Date:01/13/26
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative operating cash flow), partially offset by a stable, low-leverage balance sheet. Technicals show strong recent momentum with the stock trading above major moving averages, but overbought signals raise near-term risk. Valuation remains unattractive/unclear due to negative earnings (negative P/E) and no indicated dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage provides durable financial flexibility to support R&D and absorb industry cyclicality. A strong equity base (~83.6%) gives optionality for strategic investments, partnerships, or M&A without incurring heavy interest burdens while management works to restore profitability.
Negative Factors
Declining revenue growth
Sustained revenue decline reduces scale advantages and limits the company’s ability to invest in product development, sales, and data acquisition. If top-line contraction continues, margin recovery and the path to profitability become harder, increasing financing needs and strategic execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage provides durable financial flexibility to support R&D and absorb industry cyclicality. A strong equity base (~83.6%) gives optionality for strategic investments, partnerships, or M&A without incurring heavy interest burdens while management works to restore profitability.
Read all positive factors
Yidu Tech, Inc. (2158) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.56B
Dividend YieldN/A
Average Volume (3M)6.50M
Price to Earnings (P/E)64.8
Beta (1Y)1.75
Revenue Growth16.87%
EPS GrowthN/A
CountryHK
Employees754
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,072,818,200
10 Day Avg. Volume6,345,530
30 Day Avg. Volume6,499,248
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)1.25
Price to Sales (P/S)5.73
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.80Price Target Upside21.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$972.31M
Yidu Tech, Inc. Business Overview & Revenue Model
Company Description
Yidu Tech Inc. is a technology company that develops and deploys healthcare solutions leveraging big data and artificial intelligence. Its operations extend across Mainland China, Brunei, and other global regions. The company's business activities...
How the Company Makes Money
null...
Yidu Tech, Inc. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 790.51M | 714.98M | 807.08M | 804.70M | 1.24B |
| Gross Profit | 288.01M | 239.18M | 339.44M | 274.50M | 396.89M |
| EBITDA | -54.86M | -89.62M | -170.77M | -579.98M | -715.70M |
| Net Income | 70.15M | -117.79M | -194.94M | -627.97M | -762.32M |
Balance Sheet | |||||
| Total Assets | 4.30B | 4.69B | 4.82B | 4.91B | 4.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.22B | 3.30B | 3.70B | 3.75B | 3.77B |
| Total Debt | 76.78M | 129.54M | 95.20M | 14.13M | 52.16M |
| Total Liabilities | 583.08M | 711.37M | 732.21M | 755.36M | 715.34M |
| Stockholders Equity | 3.63B | 3.92B | 4.02B | 4.08B | 3.99B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -350.78M | -367.20M | -374.60M | -672.14M |
| Operating Cash Flow | 0.00 | -248.81M | -326.38M | -357.01M | -614.68M |
| Investing Cash Flow | 0.00 | 116.71M | 466.90M | -2.34B | 3.39B |
| Financing Cash Flow | 0.00 | 20.04M | 82.21M | 361.45M | -35.23M |
Yidu Tech, Inc. Technical Analysis
Negative
5.58
Price Trends
5.27
Negative
5.50
Negative
5.59
Negative
Market Momentum
>-0.01
Negative
44.34
Neutral
33.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.58 is above the 20-day moving average (MA) of 4.96, above the 50-day MA of 5.27, and below the 200-day MA of 5.59, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 33.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.
Yidu Tech, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$5.90B | 14.60 | 6.89% | 2.72% | 15.04% | 5.57% | |
56 Neutral | HK$16.84B | 36.57 | 3.87% | ― | 13.84% | 146.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.02B | -14.47 | -2.13% | 2.02% | 0.69% | -1.39% | |
45 Neutral | HK$5.56B | 64.81 | -2.28% | ― | 16.87% | ― | |
44 Neutral | HK$757.69M | -16.11 | -11.58% | ― | -7.24% | 53.79% |
* Healthcare Sector Average
HK:2158
Yidu Tech, Inc.
4.92
-1.65
-25.11%
HK:1833
Ping An Healthcare and Technology Company
7.50
-2.20
-22.68%
HK:9960
Kindstar Globalgene Technology, Inc.
1.00
-0.28
-22.00%
HK:2192
Medlive Technology Co., Ltd.
7.59
-6.99
-47.93%
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.86
-0.04
-4.44%
HK:2506
Xunfei Healthcare Technology Co., Ltd.
69.10
-45.80
-39.86%
Yidu Tech, Inc. Corporate Events
Yidu Tech Wins RMB12.89 Million Hainan Infectious Disease Platform Contract
Apr 13, 2026
Yidu Tech Inc. said its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. has won a bid to build the Phase II Provincial Coordinated Regional Infectious Disease Monitoring, Warning and Emergency Command Information Platform in Hainan Province, a...
Yidu Tech Wins RMB4.88 Million AI Project With Beijing Cancer Hospital
Apr 7, 2026
Yidu Tech Inc. has announced that its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. has won a bid to develop an AI-empowered Bank-Hospital collaboration project for Beijing Cancer Hospital, with a contract value of about RMB4.88 million. The...
Yidu Tech Authorizes On-Market Share Purchases for Award Scheme
Mar 26, 2026
Yidu Tech Inc. has authorized its board-appointed trustee to purchase company shares on the open market under its post-IPO share award scheme, adopted in 2020 and amended in 2023. The acquired shares will be reserved to support equity-based compen...
Yidu Tech Formalizes Nomination Committee Governance Framework
Mar 23, 2026
Yidu Tech Inc. has set out formal terms of reference for its nomination committee, a board-level body responsible for identifying and recommending director candidates, overseeing evaluation of the board’s performance and developing nominatio...
Yidu Tech executive director Dr. Xie Li to step down in February 2026
Feb 13, 2026
Yidu Tech Inc. has announced that executive director Dr. Xie Li will resign from the board with effect from 13 February 2026 to focus on personal matters, according to a company statement. Dr. Xie has indicated she has no disagreement with the boa...
Yidu Tech Reshapes Board and Committee Roles to Bolster Governance
Feb 13, 2026
Yidu Tech Inc. has updated its board composition effective 13 February 2026, confirming a three-tier structure of executive, non-executive and independent non-executive directors led by Chairlady Gong Yingying and CEO Xu Jiming. The board also inc...
Yidu Tech Confirms Qualification of Joint Company Secretary and Retains Dual Role for Governance
Feb 3, 2026
Yidu Tech Inc. announced that the Hong Kong Stock Exchange has confirmed joint company secretary Ms. Feng Xiaoying now fully meets the qualifications required under the Listing Rules to serve as company secretary. Despite this, the company will re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.